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Abstract
Psoriasis is a chronic, immune-mediated disease resulting from interactions of genetic 
background with environmental triggering factors, such as trauma, infections and drugs. 
Dendritic cells, activated T-cells toward a Th1 and Th17 response and inflammatory cyto-
kines [tumor necrosis factor (TNF)-alpha, IL-6, -12, -17, -22 and -23] are the key factors in 
psoriasis pathogenesis. Patients diagnosed with psoriasis are at increased risk of infection 
due to the nature of disease and immunosuppressive therapies. Vaccination is recom-
mended to prevent infections in patients with psoriasis. Additionally, vaccines such as 
Mycobacterium vaccae, live attenuated varicella zoster virus and Leishmania amastigotes 
have been reported to induce improvement in psoriasis patients. It has been suggested 
that vaccines, targeting molecules in the immunopathogenesis of psoriasis, may be a new 
treatment option for psoriasis patients without any serious side effects. However, induc-
tion or worsening of the psoriasis and psoriatic arthritis followed by some vaccines (e.g., 
influenza, rubella, tetanus, BCG) has also been reported in the literature. In this review, 
we focus on the vaccines in psoriasis in terms of their both triggering and therapeutic 
effects.
Keywords: psoriasis, antimicrobial vaccination, recommended vaccines, triggering 
vaccines, therapeutic vaccines
1. Introduction
Psoriasis is a chronic, immune-mediated disease with a prevalence of 2–3% in adult popu-
lation. Psoriatic arthritis affects approximately 11% of psoriasis patients, and cardiovascular 
disease is increased [1]. Psoriasis disease is caused by the interactions of genetic background 
with various environmental triggering factors. HLA-Cw6 allele in PSORS1, the most associated 
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gene with psoriasis, encodes a major histocompatibility complex I allele that is the major factor 
for antigen presentation of intracellular peptides to the immune system [2].
Several environmental factors, such as trauma (Koebner effect), infections, obesity, smok-
ing and some medications, play a role in the onset of psoriasis. Guttate psoriasis is related 
to streptococcal throat infections as two-thirds of patients have a history of throat infection 
nearly 2 weeks before the eruption [3, 4]. A homology between streptococcal M protein and 
human keratin 17, which is upregulated in the skin of psoriasis, has been reported. In the basis 
of this finding, T-cells cross-reacting with human keratin and streptococci have been detected 
in HLA-CW6-positive psoriasis patients, raising the possibility that psoriasis is an autoim-
mune disease [5].
In the initial phase of the disease, certain dendritic cell (DC) populations such as plasma-
cytoid DCs (pDC) and dermal myeloid DCs are activated and produce the key psoriasis 
effector cytokines IL-12 and IL-23. Self-DNA or self-RNA from damaged keratinocytes and 
the antimicrobial peptide LL37 stimulate pDCs, through Toll-like receptor (TLR) 9 or TLR7/8 
and IFN-alpha production is triggered. The stimulation of pDCs is followed by differentia-
tion and activation of myeloid DCs, which express cytokines IL-12, tumor necrosis factor 
(TNF)-alpha, TGF-beta and IL-6. These cytokines induce T-cells to polarize into Th1 and 
Th17 subtypes, with suppressing of regulatory T-cells [1, 2, 6, 7]. CD4+ T-cells secreting IL-17 
are classified as a different T-helper population called Th17 cells, which are critical in psoria-
sis pathogenesis. Th17 cells produce IL-17A and IL-17F, and Th1 cells produce TNF-alpha, 
IFN-gamma, IL-12, IL-22 and IL-23 that promote the pathological changes in psoriasis skin 
lesions [2, 8].
For psoriasis patients with localized disease, topical treatments including corticosteroids, 
vitamin D derivatives, tazarotene, anthralin, tar, calcineurin inhibitors, keratolytic agents 
and urea are the first-line therapy [9]. Phototherapy is a mainstay option particularly 
for patients resistant to topical treatments with widespread disease [10]. In cases with 
moderate-to-severe psoriasis resistant to any of these treatments, conventional systemic 
therapy is done with methotrexate (MTX), cyclosporine, fumaric acid esters and acitretin. 
In patients who have failed to respond to conventional systemic therapies and photother-
apy or the person is intolerant to, or has a contraindication to these treatments, biologic 
immunotherapy is used. There are several agents such as TNF-alpha inhibitors (etaner-
cept, infliximab and adalimumab) and ustekinumab that are available in the treatment of 
psoriasis [11].
Vaccination is a proven way of reducing the incidence of serious or life-threatening infectious 
disease in general population and in patients with immune-mediated inflammatory disease. 
Vaccines are recommended for psoriasis patients due to their susceptibility to infections [12]. 
The data emphasize that especially some types of vaccines may trigger an exacerbation of 
psoriatic skin lesions or induce improvement in psoriasis [1, 13].
In this review, we aim to summarize the vaccines in psoriasis in terms of their both triggering 
and therapeutic effects.
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2. Vaccines recommended for psoriasis patients
Patients diagnosed with psoriasis are at risk of infections owing to the nature of disease and 
immunosuppressive therapies [12, 14]. Therefore, the medical board of the National Psoriasis 
Foundation recommends vaccinations in compliance with recommendations of the Advisory 
Committee for Immunization Practices to prevent infections [12]. Types of vaccines can be 
categorized as live and inactivated vaccines (Table 1) [12, 14].
Live vaccines, which contain attenuated natural pathogens, are contraindicated in immu-
nocompromised patients and should be given 2 or 4 weeks before the immunosuppres-
sive therapy. Additionally, immunosuppressive medications should be stopped generally 
3 months before the immunization with live vaccines [12, 14]. However, a few reports sug-
gest that some live vaccines such as yellow fever vaccine in patients receiving MTX may 
be safe [15]. More research is needed for safety of live vaccines in immunocompromised 
patients [12, 15]. Inactivated vaccines are safe for patients on immunomodulatory therapy 
due to their noninfectious content but vaccine response may be suboptimal [12, 14, 16]. 
It has been reported that the antibody response ratio following seven-valent conjugate 
pneumococcal vaccination was significantly higher in controls when compared to patients 
treated with MTX or MTX combined with TNF inhibitors. On the other hand, in the same 
study, patients treated with TNF inhibitors as monotherapy had numerically lower but not 
significantly different antibody levels, compared to controls [17]. In a study, ustekinumab 
did not impair the immune response to pneumococcal and tetanus toxoid vaccines in pso-
riasis patients [18]. In another study, efalizumab caused a nearly threefold decrease in the 
antibody response to tetanus toxoid vaccine while not changing the immune response to 
pneumococcal polysaccharide vaccine [19]. Immune responses to pneumococcal polysac-
charide vaccine in patients with chronic plaque psoriasis treated with alefacept were similar 
to those seen in healthy subjects [20].
Inactivated or inert vaccines Live vaccines
Salk poliomyelitis vaccine






















Table 1. Types of vaccines.
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In a study assessing the seasonal 2012 influenza vaccination among patients with psoriatic arthri-
tis and psoriasis, usage of TNF-alpha blockers or disease-modifying antirheumatic drugs did not 
affect the response rate [21]. Annual immunization with inactivated influenza vaccine is recom-
mended for psoriasis patients on immunosuppressive treatment due to high mortality rates of 
seasonal influenza [12, 22]. In a French study on 1308 psoriasis patients, Sbidian et al. reported 
that 19% of patients received the 2009 monovalent H1N1 vaccine. Only 33% of the patients treated 
with biologics were vaccinated [23]. The vaccination rate of influenza vaccine in 2010/2011 was 
found 28% among 1299 patients with psoriasis or psoriatic arthritis in Germany. Thirty-eight 
percent of the patients were on biological therapy at the time of vaccination [22]. Despite the 
recommendations, the vaccination coverage was low in psoriasis patients in both studies [22, 23].
Zoster vaccine, a live attenuated vaccine, is recommended for use in immunocompetent individ-
uals 60 years of age or older to reduce the risk and severity of herpes zoster (HZ) [12]. Increased 
incidence of HZ has been reported in psoriasis patients receiving combination treatment with 
biologic medications and MTX while biologic or systemic agents as monotherapy did not increase 
the risk of HZ [24]. Zhang et al. reported that zoster vaccination was not related to increased risk 
of HZ in patients with immune-mediated disease including psoriasis under biological therapy 
[25, 26]. However, it was emphasized that infliximab increases the risk of HZ in most of the 
cohort studies while the risk of HZ in patients receiving etanercept, adalimumab or ustekinumab 
therapy is not clear [27]. Yun et al. indicated that the use of biologic agents and systemic ste-
roids in patients with autoimmune and inflammatory diseases increased the risk of HZ [28]. 
Consequently, HZ vaccination should be considered for patients who are going to receive bio-
logical agents especially infliximab and combination treatment with MTX therapy. Additionally, 
the vaccine should be administered before initiation of the immunosuppressive therapy [24, 27].
As a conclusion, it has been reported that immunization status, including Haemophilus influenza, 
hepatitis A and B, human papillomavirus, influenza, Neisseria meningitides and Streptococcus pneu-
moniae should be assessed in all patients with moderate-to-severe psoriasis [12]. Recommendations 
for vaccination of patients diagnosed with psoriasis are given in Table 2 [12, 14].
Type of vaccine Before therapy On therapy
Inactivated vaccines
Influenza Vaccinate with inactivated or live attenuated 
vaccine
Annual inactivated influenza
Human papillomavirus Recommended for male and female < age 26 years Same
Hepatitis A For selected individuals at high risk (diabetes, liver 
disease, injecting drug users, homosexual men, 
employees or residents in institutional settings)
Same, test for serology after 
vaccination
Hepatitis B For individuals at high risk and without evidence 
of disease and immunity
Use high-dose vaccine, test for 
serology after vaccination
Pneumococcal Immunization with 23-valent pneumococcal 
polysaccharide vaccine
Immunization with 13-valent 
pneumococcal conjugate 
vaccine followed by 23-valent 
pneumococcal polysaccharide 
vaccine if not given prior
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3. Triggering effect of vaccines on psoriasis
As mentioned above, basis on a genetic predisposition, various environmental factors may 
cause development of psoriasis in patients who are in latent period. Physical or chemical fac-
tors, infections and various types of medications are the most important among these, and 
they may affect the course of psoriasis by many different mechanisms [13]. Triggering vac-
cines on psoriasis and psoriatic arthritis are summarized below.
3.1. Koebner effect
Various types of skin trauma with subsequent development of new psoriasis lesions about 
10 days later are known as ‘Koebner-phenomenon’ [29]. In a study evaluating the relation 
between ‘Koebner-phenomenon’ and intradermal antigens, 30 psoriasis patients and 20 con-
trol subjects were firstly determined for Koebner status and then were tested with intrader-
mal injections of purified protein derivative, Candida, mumps, mixed respiratory vaccine 
and saline control solutions. Two psoriasis patients were Koebner positive and developed 
psoriasis at all five injection sites. Besides, in five Koebner negative patients, local psoriasis 
lesions were observed in at least one injection site of different antigens. These findings were 
interpreted that some psoriatic patients may have individually specific sensitivity to different 
antigens to trigger the cellular immune response in psoriasis [30].
Additionally, in a recent placebo-controlled study, evaluating the ‘nontypeable Haemophilus 
influenza protein vaccine’, a psoriasis case was reported to be associated with injection of 
saline placebo at 114 days post-dose 3 in the placebo group indicating the Koebner effect [31].
Type of vaccine Before therapy On therapy
Haemophilus influenza 
type b
Unvaccinated individuals can be vaccinated Same
Diphtheria-tetanus-
pertussis
Booster is recommended every 10 years and for 
high-risk wounds, offer before therapy
Same
Meningococcal For selected individuals at high risk (asplenia, 
complement deficiency, group living situation)
Same
Poliomyelitis For selected individuals at high risk (healthcare 
workers or laboratory personnel)
Same
Live vaccines
Varicella zoster Test for serology before initiation of therapy, if 
negative, offer vaccination
Contraindicated
Herpes zoster 1 dose for adults ≥50 years Contraindicated
Measles-mumps-rubella Assessment of immunization by history and 
serology before initiation of therapy, if negative, 
offer vaccination
Contraindicated
Table 2. Recommendations for vaccination of patients diagnosed with psoriasis before or on systemic immunosuppressants.




BCG is a live attenuated strain of Mycobacterium bovis, which has been used as local immuno-
therapy for bladder cancer since 1976 [32]. In 1955, a psoriasis case was described following 
BCG vaccination under the name of ‘psoriasis vaccinalis’ [33]. A male with psoriatic arthropa-
thy after BCG immunotherapy for bladder carcinoma and a psoriasis case after BCG vac-
cination are the other early reports associated with BCG vaccination [34, 35]. Koca et al. also 
defined a 7-year-old boy with guttate psoriasis-like lesions developed 1 week after the BCG 
vaccination [35]. Takayama et al. presented a 6-month-old girl with psoriatic skin lesions ini-
tially appeared on the vaccination site 1 month after the BCG vaccination. In that case, expres-
sion of activated phospho-Stat-3 was found in the epidermal keratinocytes of the lesional skin. 
Mycobacterial heat shock proteins have been reported to stimulate IL-6, which promotes the 
development of Th17 cells. Thus, the authors speculated that BCG vaccination might medi-
ate the generation of IL-22-producing Th17 cells and lead to activation of epidermal Stat-3 
and psoriatic skin lesions [36]. In addition, an 80-year-old man with bladder carcinoma was 
reported with erythrodermic pustular psoriasis triggered by intravesical BCG immunother-
apy. The similar mechanism with Th1 and Th17 cells generation after BCG vaccination was 
thought to play an important role in the pathogenesis of psoriasis [32].
3.3. Tetanus-diphtheria (Td) vaccination
A case of 50-year-old psoriasis patient in remission was described as guttate psoriasis 1 week 
after the Td vaccination [37]. Td vaccine has shown to induce IL-6 production, which stimu-
lates Th17 cells, having a key role in psoriasis pathogenesis [37, 38]. It was suggested that this 
mechanism was the triggering cause in this case [37]. In a case-control study evaluating the 
potential risk factors for the onset of psoriatic arthritis, exposure to rubella (OR = 12.4, 95% 
CI = 1.2–122.14) and tetanus (OR = 1.9, 95% CI = 1.0–3.7) vaccines was reported at a higher 
frequency in psoriatic arthritis group as compared to the psoriasis group without arthritis [39].
3.4. Influenza vaccination
Shin et al. described a 26-year-old woman with multiple erythematous scaly macules scat-
tered on the extremities and trunk compatible with guttate psoriasis following injection of an 
inactivated split-virus influenza A/H1N1 vaccine without adjuvant [40]. Güneş et al. reported 
43 patients suffering from psoriasis in that 36 of them had exacerbation of pre-existing pso-
riasis while disease first appeared in the remaining seven patients after influenza vaccination 
in the 2009–2010 season. Thirty-seven of these patients had mixed plaque type and guttate 
psoriasis, three of them suffered from palmoplantar psoriasis, and another three of them had 
scalp psoriasis. Although there is the lack of control group and follow-up evaluations in that 
study, they suggested that their observations may support the association between influenza 
vaccination and the development of psoriasis due to the short-time onset of psoriasis after 
vaccination and the lack of other possible triggers [13].
There is also a cross-sectional study investigating a total of 1125 cases for the onset or flare of 
psoriasis occurring within 3 months following the 2009 monovalent H1N1/seasonal vaccination 
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through a national survey in France. The overall influenza vaccine coverage was found 19% 
in this population. Ten patients were reported with a psoriasis of new onset (n = 7) or with a 
worsening of previously diagnosed psoriasis (n = 3) within a median time period of 8 days after 
vaccination. Due to the uncertainties about the actual number of psoriatic patients undergoing 
vaccination, underestimation of the incidence due to underreporting and underdiagnosis and 
the lack of control group, the data could not provide a definitive conclusion about an associa-
tion between vaccination and the psoriasis. However, the authors claimed that even if it is not a 
very strong risk, influenza vaccination is associated with psoriasis flare [41].
In another study, the effects of seasonal influenza vaccination in psoriatic arthritis patients 
under anti-TNF-alpha therapy were evaluated. 1 month after the vaccination (T1), patie-
nts (n = 25) had statistically significant increase in tender joint count (TJC) (p = 0.009) 
and erythrocyte sedimentation rate (ESR) (p = 0.046) as compared to baseline. Statistically 
significant difference was observed only in TJC (p = 0.01) 3 months after the vaccination 
(T3). Additionally, vaccinated patients showed a significant increase in TJC (p = 0.004), 
ESR (p = 0.007), Health Assessment Questionnaire (p = 0.023), patient global assessment 
(p = 0.013) and physician global assessment (p = 0.026) when compared to nonvaccinated 
patients (n = 25) at T1. At T3, similar findings were observed for only ESR (p = 0.006) and 
physician global assessment (p = 0.013) when data were analyzed between two groups. In 
conclusion, the authors suggested that influenza vaccine may have a short lasting trigger-
ing effect on psoriatic arthritis patients [42].
3.5. Adenovirus vaccination
In a retrospective study, which evaluated the possible side effects related to adenovirus types 
4 and 7 in military recruits, psoriasis (21 versus 7 cases) was found more frequently (RR = 2.44, 
95% CI = 1.13–5.31) in the vaccinated group (n = 100,000) when compared to unvaccinated 
group (n = 100,000) [43].
4. Therapeutic effects of vaccines on psoriasis
Both conventional systemic treatments and biologic agents are related to serious side effects. 
The biologic immunotherapy agents act by inhibiting over-expressed T-cell activity by reducing 
T-cell numbers, T-cell trafficking or immune deviation and blocking the activities of proinflam-
matory cytokines, which may lead to severe infections, myelodegenerative and autoimmune 
disorders [29]. Additionally, over the past few years, various John Cunningham virus (JCV) 
associated brain syndromes have been reported as a result of increased usage of the immuno-
modulatory medications [44]. The progression in the enlightenment of the immunopathogene-
sis of psoriasis may provide new therapeutic options that do not have immunosuppressive side 
effects. Vaccination is a progressing therapy option for psoriasis and the other chronic inflam-
matory disorders such as multiple sclerosis, rheumatoid arthritis and atherosclerosis, which 
are termed as noncommunicable diseases [1, 45, 46]. It has clearly demonstrated that vaccines 
have the ability to activate effectors such as dendritic cells and T lymphocytes, which are also 
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involved in psoriasis pathogenesis [41]. Noncommunicable disease vaccines target cells, pro-
teins or other molecules that are related to these disorders and modulate the immune system, 
similar to traditional vaccines [45].
Approximately two-thirds of guttate psoriasis patients and a quarter of chronic psoriasis 
patients have an association with streptococcal throat infections. Fry et al. claimed that vac-
cination against Streptococcus pyogenes as well as the other possible microorganisms that 
trigger psoriasis may be a new way to prevent psoriasis [3, 4]. It has also been suggested that 
psoriasis may benefit from development of a T-cell receptor peptide vaccine [47].
As we mentioned before, IL-17 has been shown to play an important role as a proinflammatory 
cytokine in psoriasis. IL-17 is demonstrated as a ‘target antigen’ for the treatment of autoim-
mune disorders and psoriasis in preclinical experiments in animal models and in clinical trials 
[48]. Dallenbach et al. showed that immunization with Qβ-IL-17, a virus-like particle-based 
vaccine, generated IL-17-specific IgG in mice. In order to evaluate the role of hypermutation 
and affinity maturation, they mutated the hypermutated antibody back to germline sequence, 
producing a set of two antibodies with VH regions differing in three aminoacids, but recogniz-
ing the same epitope. They showed that both the hypermutated and the germline antibody sig-
nificantly neutralized IL-17 and blocked its biological activity in vivo. They also demonstrated 
that both antibodies were able to reduce imiquimod-induced psoriatic skin inflammation, 
indicating that vaccination against IL-17 may be a new therapeutic option for psoriasis [49].
Over-expression of ß-defensin 2, known as a skin antimicrobial peptide, has been reported to 
be associated with psoriasis [50]. In a recent study, serum ß-defensin 2 levels have been found 
to correlate with IL-17A levels and psoriasis area severity index (PASI) scores in psoriatic 
patients [51]. Additionally, García-Valtanen et al. demonstrated that ß-defensin 2 improves the 
DNA vaccine efficacy due to its adjuvant-like effects besides its antiviral and immunomodula-
tory properties in a study of zebrafish. They claimed that this psoriasis-related peptide might 
be used as an adjuvant in DNA vaccination to improve the efficacy of viral vaccines [50].
The TNF-alpha-induced protein 3 (TNFAIP3) is an anti-inflammatory factor that inhibits NF-κB 
activation in T-cells. In a few studies, it was reported that expression of TNFAIP3 mRNA was 
significantly higher in patients with mild psoriasis than in the patients with severe psoriasis, 
suggesting that TNFAIP3 gene may be a ‘target’ molecule for psoriasis therapy [52, 53]. There 
are also reported studies, which are mentioned below, about the usage of vaccines on psoriasis. 
4.1. Mycobacterium vaccae
Mycobacterium vaccae, a nonpathogenic organism usually applied as a heat-killed suspension, 
has been used as an adjunct immunotherapy for tuberculosis and leprosy [54]. The immuno-
therapy trials began after discovery of the therapeutic effect of M. vaccae injection in psoriasis 
skin lesions of leprosy patients with concomitant psoriasis [55].
A placebo-controlled study in patients with chronic plaque psoriasis evaluated the potential 
beneficial effects of M. vaccae immunotherapy. The study group of 31 patients received a dose 
of M. vaccae, and placebo group of 24 patients were given a dose of tetanus toxoid. The mean 
PASI values at both 3 and 6 months for the M. vaccae group were significantly lower than their 
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entry values (p < 0.001 and p < 0.005), while the tetanus toxoid group did not reach this signifi-
cance at any time. The failure of the patients to return for follow-up visits and the selection of 
tetanus toxoid as a placebo were the problems of the study. In spite of these limitations, the 
authors claimed that the study showed a significant improvement (p < 0.005) in the PASI after 
a single injection of M. vaccae [56]. A subsequent study of 24 patients, PASI scores of whom 
showed significant reduction (p < 0.001) at 12 and 24 weeks in comparison with the initial 
PASI score after two intradermal inoculations of M. vaccae, confirmed these findings [56].
A study performed on 36 patients with psoriatic arthritis randomized the patients to receive 
two intradermal injections of 50 µg delipidated, deglycolipidated M. vaccae (PVAC) or pla-
cebo and followed up them for 24 weeks. The psoriatic arthritis response criteria at either 12 
or 24 weeks were achieved by 50% (9/18) in both placebo and PVAC group. There was only a 
significant change in the visual analogue scale over time between the two groups. The mean 
score had decreased by 19.2 mm in the PVAC group and increased by 4.8 mm in the placebo 
group (p = 0.006). Consequently, the authors claimed that PVAC was not an effective immuno-
therapy for psoriatic arthritis [57]. Likewise, a placebo-controlled study did not show a clearly 
efficacy of PVAC in the treatment of psoriasis patients, because 75% PASI was similar among 
the studied groups at week 12 [55].
Mycobacterium w is a nonpathogenic, rapidly growing, cultivable strain of atypical mycobac-
teria and has been used as an adjuvant immunotherapy for leprosy, tuberculosis and human 
immunodeficiency virus, like M. vaccae [58]. The efficacy of Mycobacterium w in psoriasis was 
also evaluated by some trials [58, 59]. In a study of 36 psoriasis patients, 24 of them were in the 
study group and received two doses of 0.1 ml of heat-killed Mycobacterium w at 3 weekly inter-
vals. The remaining 12 patients in the control group were given of normal saline at the same 
weeks. The study showed marked improvement (>50% reduction in PASI score) in the four of 
24 cases (16.6%) and moderate improvement (25–50% reduction) in 15 cases (62.5%) at the end 
of the 4 months. No improvement was seen in the 4 of 24 patients, and the disease got worse in 
1 patient. There were no significant side effects, although five patients had new lesions at the 
site of injection [59]. On the other hand, in another study that included 45 psoriasis patients 
who received a total of four doses of Mycobacterium w, the percentage reduction of PASI score 
was only 33% at the end of 12 weeks. Additionally, at the beginning of the study, PASI scores 
showed increase in nine patients, four of whom were severe and received an alternative ther-
apy [58]. The results were in contrast to findings of the prior study by Rath et al. [58, 59].
The mechanism of mycobacterium immunotherapy leads to improvement in psoriasis is 
not known exactly. Lehrer et al. suggested that the decreasing effect of TNF-alpha might 
cause clinical improvement in psoriasis patients treated with M. vaccae immunotherapy 
[56]. According to Dalbeth et al., increased IL-10 levels after the PVAC injection may lead to 
improvement in psoriasis due to inhibition of T-cell function and reduction of IFN-gamma 
and TNF-alpha production [57].
4.2. Leishmania amastigotes
In a trial about a vaccine for cutaneous leishmaniasis, O’Daly et al. observed 100% clinical 
remission of a psoriatic lesion in one patient after third vaccination. After this discovery, 
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they performed an open-label, single-center study to evaluate the leishmaniasis vaccine 
(AS100®) in 2770 psoriasis patients. When baseline PASI values were compared with the 
post-treatment values, PASI 100 was achieved in 23%, PASI 75 in 45%, PASI 50 in 13%, 
PASI 10 in 9% and <PASI 10 was determined in 3% of patients. The most common adverse 
effects were pain and nodule formation, which were injection side related. The other sys-
temic adverse effects were considered as mild and moderate in severity. Similar results 
were observed in a second, double-blind, placebo-controlled study, performed by the same 
group [60]. In a subsequent study, O’Daly et al. evaluated further purified vaccines, result-
ing in seven chromatography fractions per four Leishmania species. They suggested that 
three fractions from L. brasiliensis and four fractions from L. chagasi demonstrated the maxi-
mal therapeutic effect on psoriasis [61]. O’Daly et al. also revealed that regarding to PASI 
values, certain lymphocyte subtypes decreased in peripheral blood cells suggesting migra-
tion from the blood to the skin while others increased suggesting activation by unknown 
antigens. After injection seven doses of AS100 vaccine, lymphocyte subtypes CD3+CD8−, 
CD8+CD3−, HLA+CD8−, CD8+HLA+ and CD4+CD8− increased as PASI values decreased 
and clinical improvement was seen, while CD8+CD3+, CD8+HLA−, CD19 and CD8+CD4+ 
decreased in peripheral blood cells. These results suggested that treatment with Leishmania 
antigens leads lymphocytes to traffic between blood and skin and activates T-cells in skin 
plaques, contrary to current treatments killing T-cells in psoriasis patients [62]. Another 
open-label, single-center study conducted by O’Daly et al. showed clinical remission in 
patients with psoriatic arthritis after the average number of 9.9 ± 4.8 doses of AS100 treat-
ment [63].
4.3. Live attenuated varicella vaccine
A placebo-controlled study was conducted by El-Darouti et al. to evaluate the adjuvant effect 
of live attenuated varicella vaccine (Varilrix®) in patients with resistant severe psoriasis after 
their observation of improvement in one patient with severe psoriasis following a chickenpox 
infection. Study group received four doses of Varilrix® once every 3 weeks before low-dose 
cyclosporine (2.5 mg/kg/day) while control group received four doses of subcutaneous saline 
as placebo. Study group demonstrated significantly higher improvement in their PASI values. 
According to El-Darouti et al., the hypotheses explaining the mechanism of live attenuated 
varicella vaccine on psoriasis are given as below [64]:
• The stimulating effect of varicella zoster virus on the humoral response by Th-2 cells and 
subsequent downregulation of the Th-1 response,
• The inhibitory effect of IFN-alpha on Th-17 cells by peripheral blood cells exposed to vari-
cella zoster virus antigen,
• The upregulation of regulatory T-cells that have inhibitory effects on psoriasis after receiv-
ing varicella vaccine.
Subsequently, El-Darouti et al. reported that live attenuated varicella vaccine is effective in 
psoriasis when used with low-dose cyclosporine by acting possibly on the Th17/ regulatory 
T-cells balance [65].
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5. Conclusion
Vaccination is an effective tool for reducing the incidence of serious or life-threatening infec-
tious disease [45]. Patients diagnosed with psoriasis are at risk of infections due to the nature 
of disease and immunosuppressive therapies [12, 14]. For this reason, the medical board of the 
National Psoriasis Foundation recommends vaccination for patients diagnosed with psoriasis 
in compliance with recommendations of the Advisory Committee for Immunization Practices 
[12]. Besides, vaccines such as M. vaccae, live attenuated varicella zoster virus and Leishmania 
amastigotes have been reported to be effective in the treatment of psoriasis. Vaccines, regu-
lating the inflammatory response in psoriasis, may be a new therapeutic option for psoriasis 
patients without any serious side effects. On the other hand, the data emphasize that especially 
some types of vaccines may trigger an exacerbation of psoriatic skin lesions. The very low inci-
dence of psoriasis following vaccination reveals the safe profile but some authors recommend 
the follow-up of such individuals [13]. Further large-sized and controlled clinical research stud-
ies need to be carried out to confirm the relationships between psoriasis and the vaccination.
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